METAVAX® our proprietary platform to develop highly immunogenic chimeric VLP-based vaccines presenting customer’s antigen target. Our platform is built on the WHO recommended production host Hansenula polymorpha and our unique duck hepatitis B virus like particle (dHBs).

Download our METAVAX® brochure.